Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2022 Results Earnings Conference Call May 4, 2022 8:00 AM ET

Company Participants

Ron Moldaver - Investor Relations

Jim Mullen - Chief Executive Officer

Mark Shearman - Chief Scientific Officer

Michelle Robertson - Chief Financial Officer

Charlene Stern - General Counsel

Conference Call Participants

Joon Lee - Truist

Joel Beatty - Baird

Dae Gon Ha - Stifel

Steven Seedhouse - Raymond James

Rick Bienkowski - SVB Securities

Luca Issi - RBC Capital

Liisa Bayko - Evercore ISI

Operator

Good morning and welcome to the Editas Medicine First Quarter 2022 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the company’s request.

I would now like to turn the call over to Ron Moldaver, Investor Relations at Editas Medicine.

Ron Moldaver

Thank you, Paul. Good morning, everyone. And welcome to our first quarter 2022 conference call. Earlier this morning, we issued a press release providing our financial results and recent corporate updates. A replay of today’s call will be available on the Investors section of our website, approximately two hours after its completion. After our prepared remarks, we will open the call for Q&A.

As a reminder, various remarks that we make during this call about the company’s future expectations, plans and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent annual report on Form 10-K, which is on file with the SEC as updated by our subsequent filings.

In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as required by law, we specifically disclaim any obligation to update or revise any forward-looking statements, even if our views change.

Now, I will turn the call over to our Chief Executive Officer, Jim Mullen.

Jim Mullen

Thanks, Ron and good morning, everyone. I am joined today by several members of the Editas executive team, including Mark Shearman, our Chief Scientific Officer; Michelle Robertson, our Chief Financial Officer, and Charlene Stern, our General Counsel.